Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic
At Tessa Therapeutics, the big idea has been to adapt virus-specific T cells (VST) to target virally-associated tumors, and swarm cancer cells. Researchers believe these VSTs can be versatile, making superior CAR-Ts that can then be combined with an oncolytic virus and a checkpoint inhibition strategy. In its latest preclinical trial, the Singapore-based biotech has spotlighted one such “all-in-one” approach that they are now taking into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
